Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Jan;28(1):22–28. doi: 10.1007/BF00205796

Modification of tumor cells by a low dose of Newcastle disease virus

II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation

Hansjörg Schild 1, Paul von Hoegen 1, Volker Schirrmacher 1,✉
PMCID: PMC11038118  PMID: 2462467

Abstract

Augmented tumor-specific T cell responses were observed against the high metastatic murine lymphoma variant ESb when using as immunogen ESb tumor cells that had been modified by infection with a low dose of Newcastle disease virus (NDV). Such virus-modified inactivated tumor cells (ESb-NDV) were potent tumor vaccines when applied postoperatively for active specific immunotherapy of ESb metastases. We demonstrate here that immune spleen cells from mice immunized with ESb-NDV contain enhanced immune capacity in both the CD4+, CD8− and the CD4−, CD8+ T cell compartments to mount a secondary-tumor-specific cytotoxic T cell response in comparison with immune cells from mice immunized with ESb. ESb-NDV immune CD4+, CD8− helper T cells also produced more interleukin 2 after antigen stimulation than the corresponding ESb immune cells. There was no participation of either CD4+ or CD8+ virus-specific cells in the augmented response. The specificity of the T cells for the tumor-associated antigen remaind unchanged. Thus, there is the paradox that the virus-mediated augmentation of the tumor-specific T cell response in this system involves increased T helper activity but does not involve the recognition of viral epitopes as potential new helper determinants.

Keywords: Cell Response, Spleen Cell, Newcastle Disease Virus, Newcastle Disease, Antigen Stimulation

Abbreviations

CTL

cytolytic T lymphocytes

IL-2

interleukin 2

rIL-2

recombinant IL-2

mAb

monoclonal antibody

NDV

Newcastle disease virus

SSC

syngeneic spleen cell

References

  • 1.Altevogt P, Leidig S, Heckl-Oestreicher B. Resistance of metastatic tumor variants to tumor specific cytotoxic T lymphocytes not due to defects in expression of restricting MHC molecules. Cancer Res. 1984;44:5305. [PubMed] [Google Scholar]
  • 2.Austin FC, Boone CW. Virus augmentation of the antigenicity of tumor cell extracts. Adv Cancer Res. 1979;30:301. doi: 10.1016/s0065-230x(08)60900-8. [DOI] [PubMed] [Google Scholar]
  • 3.Bosslet K, Schirrmacher V, Shantz G. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice: VI. Similar specificity patterns of protective anti-tumor immunity in vivo and of cytolytic T cells in vitro. Int J Cancer. 1979;24:303. doi: 10.1002/ijc.2910240306. [DOI] [PubMed] [Google Scholar]
  • 4.Ceredig R, Lowenthal JW, Nabholz M, MacDonald HR. Expression of interleukin-2 receptors as a differention marker on intrathymic stem cells. Nature. 1985;314:98. doi: 10.1038/314098a0. [DOI] [PubMed] [Google Scholar]
  • 5.Cobbold SP, Nash AJ, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 1984;312:1698. doi: 10.1038/312548a0. [DOI] [PubMed] [Google Scholar]
  • 6.Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR, Pierres M, Fitch FW. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity to the human Leu-3/T4 molecule. J Immunol. 1983;131:2445. [PubMed] [Google Scholar]
  • 7.Forni G, Giovarelli M. Strategies for cell-mediated immunotherapy of cancer: killing or help? Immunol Today. 1986;7:202. doi: 10.1016/0167-5699(86)90104-0. [DOI] [PubMed] [Google Scholar]
  • 8.Fujiwara H, Yoshioka T, Shima J, Kozugi A, Itoh K, Hamaoka T. Helper T cells against tumor associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses. J Immunol. 1986;136:2715. [PubMed] [Google Scholar]
  • 9.Gillis S, Frem MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978;120:2027. [PubMed] [Google Scholar]
  • 10.Giovarelli M, Santoni A, Forni G. Alloantigen-activated lymphocytes from mice bearing a spontaneous “nonimmunogeneic” adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity. J Immunol. 1985;133:3596. [PubMed] [Google Scholar]
  • 11.Heeg K, Reimann J, Kabelitz D, Hardt C, Wagner H. A rapid colorimetric assay for the determination of IL-2 producing helper cell frequencies. J Immunol Methods. 1985;77:237. doi: 10.1016/0022-1759(85)90036-5. [DOI] [PubMed] [Google Scholar]
  • 12.Heicappell R, Schirrmacher V, von Hoegen P, Ahlert T, Appelhans B. Prevention of metastatic spread by postoperative immunotherapie with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int J Cancer. 1986;37:569. doi: 10.1002/ijc.2910370416. [DOI] [PubMed] [Google Scholar]
  • 13.von Hoegen P, Altevogt P, Schirrmacher V. New antigens present on tumor cells can cause immune rejection without influencing the frequency of tumor specific cytolytic T cells. 1987. Cellular Immunol. 1987;109:338. doi: 10.1016/0008-8749(87)90317-0. [DOI] [PubMed] [Google Scholar]
  • 14.von Hoegen P, Weber E, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus: I. Augmentation of the tumor cell specific T cell response in the absence of an anti-viral response. Eur J Immunol. 1988;18:1159–1166. doi: 10.1002/eji.1830180803. [DOI] [PubMed] [Google Scholar]
  • 15.Kobayashi H. Viral xenogenisation of intact tumor cells. Adv Cancer Res. 1979;30:279. doi: 10.1016/s0065-230x(08)60899-4. [DOI] [PubMed] [Google Scholar]
  • 16.Kobayashi H. The biological modification of tumor cells as a means of inducing their regression: an overview. J Biol Resp Mod. 1986;5:1. [PubMed] [Google Scholar]
  • 17.Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  • 18.Reddehase M, Suessmuth W, Moyers C, Falk W, Droege W. Interleukin 2 is not sufficient as helper component for the activation of cytotoxic T lymphocytes but synergizes with a late helper effect that is provided by I region-incompatible stimulator cells. J Immunol. 1982;128:61. [PubMed] [Google Scholar]
  • 19.Russel PH. Newcastle disease virus: the effect of monoclonal antibody in the overlay on virus penetration and the immunoselection of variants. J Gen Virol. 1984;65:795. doi: 10.1099/0022-1317-65-4-795. [DOI] [PubMed] [Google Scholar]
  • 20.Sarmiento M, Glasbrook AL, Fitch FW. IgG or IgM monoclonal antibodies reactive with different determinants of the molecular complex bearing Lyt 2 antigen block T cell mediated cytolysis in the absence of complement. J Immunol. 1980;125:2665. [PubMed] [Google Scholar]
  • 21.Schild H-J (1987) The role of CD4+ T helper cells in the induction of killer cells against a syngeneic tumor. Diploma thesis, Heidelberg
  • 22.Schild H-J, Kyewski B, von Hoegen P, Schirrmacher V. CD4+ helper T cells are required for resistence to a highly metastatic murine tumor. Eur J Immunol. 1987;17:1863. doi: 10.1002/eji.1830171231. [DOI] [PubMed] [Google Scholar]
  • 23.Schirrmacher V (1986) Postoperative activation of tumor-specific T cells as a means to achieve immune control of minimal residual disease. In: Fortner JG, Rhoads JE (eds) Accomplishments in cancer research 1986. General Motors Cancer Research Foundation, p 218–232
  • 24.Schirrmacher V, Ahlert T, Heicappell R, Appelhans B, von Hoegen P. Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy. Cancer Rev. 1986;5:19–49. [Google Scholar]
  • 25.Schirrmacher V, von Hoegen P, Heicappell R, Altevogt P. Modulations of tumor cell immunogenicity leading to increased T cell reactivity and decreased metastases formation. In: Herbermann RB, Wiltrout R, Gorelik E, editors. Immune responses to metastates. II. Boca Raton: CRC Press; 1987. pp. 1–11. [Google Scholar]
  • 26.Schirrmacher V, Heicappell R. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic immunity. Clin Exp Met. 1987;5:147–156. doi: 10.1007/BF00058060. [DOI] [PubMed] [Google Scholar]
  • 27.Schirrmacher V, Hoegen P von, Heicappell R, Griesbach A, Altevogt P (1989) Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals. Inv Met (in press) [PubMed]
  • 28.Takai Y, Kosugi A, Yoshioka T, Tomita S, Fujiwara H, Hamaoka T. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses. J Immunol. 1985;134:108. [PubMed] [Google Scholar]
  • 29.Yoshioka T, Fukuzawa M, Takei Y, Wakamiya N, Ueda S, Kato S, Fujiwara H, Hamaoka T. The augmentation of tumor specific immunity by virus help: III. Enhanced generation of tumor-specific Lyt1+2− T cells is responsible for augmented tumor immunity in vivo. Cancer Immunol Immunother. 1986;21:193. doi: 10.1007/BF00199361. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES